NEW YORK CITY (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva's generic version of Celebrex 50, 100, 200 and 400 mg capsules in U.S.
Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the U.S. FDA for all strengths.
Copyright RTT News/dpa-AFX